Press release
Prominent Shift towards Profitable Applications Cushion Demand for OTC Cough, Cold & Allergy Medicine during 2017 - 2022 | Key Players - Sanofi-Aventis, Johnson & Johnson Service, Reckitt Benckiser Group , Novartis AG, GlaxoSmithKline Plc., AstraZaneca Pl
A large number of people across the globe purchase OTC (over-the-counter) medicines for treating minor cough, cold or allergy related problems rather visiting the doctor. This has been a major reason behind the incessant sales of OTC cough, cold and allergy drugs. Many of the medicines for cold, cough and allergy fall under common categories of OTC. In order to ensure customer safety, healthcare regulatory bodies in some countries have even set guidelines for selling or purchasing of such medicines.Get Sample Copy of this Report @ https://www.factmr.com/connectus/sample?flag=S&rep_id=71
Moreover, the busy lifestyle of a modern consumer make such medicines more important as consulting a doctor for every single health issue might consume a hefty amount of time. Factors as such are playing a crucial role in further boosting the demand for OTC cough, cold and allergy medicines. In addition, growing number of immunosuppressed patients and expanding global geriatric population is anticipated to drive the growth of the market. Fact.MR’s recently published report reveals that the global cough, cold and allergy medicine market is set to witness 4.9% between 2017 and 2022. This market is estimated to stand at around US$ 37,323 Mn towards the end of the forecast period.
Asia-Pacific excluding Japan (APEJ) to Remain the Largest Market for OTC Cough, Cold and Allergy Medicines
Asia-Pacific excluding Japan (APEJ) is projected to remain the most lucrative market for OTC cough, cold and allergy medicines throughout the forecast period. In terms of revenue, APEJ is anticipated to account for an impressive share of the global market in 2017 and beyond. The region’s proximity to air pollution has led to the rise in prevalence of various respiratory disorders. Moreover, acceptance rate of OTC medicines is extremely high in the region owing to their low cost and convenience of purchase.
By drug type, antihistamine is projected to account for more than one-third share of the market in terms of revenue by 2017-end. Antihistamines drugs reduce the release of histamine from histamine-1 receptors and are commonly used for treating allergic reactions such as inflammation (redness), swelling (edema), watery eyes or runny nose and sneezing.
Browse Complete Market Report with TOC Here @ https://www.factmr.com/report/71/otc-cough-cold-allergy-medicine-market
Pharmacies will remain the leading OTC channel for sales of cough, cold and allergy medicines during the assessment period. Meanwhile, drug store OTC channel segment is expected to account for the second largest revenue share of the market by 2017-end.
By dosage, the tablet segment is estimated to account for more than 33% revenue share of the market and is expected to reach a valuation of around US$ 12,400 Mn towards the end of the forecast period.
Competition Tracking
Key companies profiled in Fact.MR’s report include Sanofi-Aventis, Johnson & Johnson Service, Inc., Reckitt Benckiser Group Plc., Novartis AG, GlaxoSmithKline Plc., AstraZaneca Plc., Pfizer Inc., Sun Pharmaceutical Industries Ltd., Prestige Brands Holdings, Inc., Procter & Gamble Co., Bristol-Myers Squib Co., Merck & Co., and Allergen. Many of these market players are actively focusing on increasing their market presence and development of more efficient products.
For any query, connect with an Analyst @ https://www.factmr.com/connectus/sample?flag=AE&rep_id=71
About Fact.MR
Fact.MR is a fast-growing market research firm that offers the most comprehensive suite of syndicated and customized market research reports. We believe transformative intelligence can educate and inspire businesses to make smarter decisions. We know the limitations of the one-size-fits-all approach; that's why we publish multi-industry global, regional, and country-specific research reports.
Contact Us
Fact.MR
11140 Rockville Pike
Suite 400
Rockville, MD 20852
United States
Email: sales@factmr.com
Web: https://www.factmr.com/
Blog: https://factmrblog.com/
Read Industry News at - https://www.industrynewsanalysis.com/
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Prominent Shift towards Profitable Applications Cushion Demand for OTC Cough, Cold & Allergy Medicine during 2017 - 2022 | Key Players - Sanofi-Aventis, Johnson & Johnson Service, Reckitt Benckiser Group , Novartis AG, GlaxoSmithKline Plc., AstraZaneca Pl here
News-ID: 1745297 • Views: …
More Releases from Fact.MR

Insulated Drinkware Market to Hit USD 2.57 Billion by 2033 | YETI, Thermos L.L.C …
The global insulated drinkware market was valued at US$ 1.39 billion in 2023 and is forecasted to expand at a 6.3% CAGR over the next ten years. Worldwide sales of insulated drinkware are projected to reach US$ 2.57 billion by 2033-end.This robust growth is driven by increasing consumer awareness of sustainability, rising participation in outdoor activities, and the growing demand for reusable, eco-friendly products amid bans on single-use plastics.
The market…

Digital Twin Market is Growing at a CAGR of 34.3% d by 2033 | Key Players: ABB L …
Digital Twin Market is valued at USD 5 billion in 2023 and is projected to expand at a compound annual growth rate (CAGR) of 34.3%, reaching USD 95 billion by 2033. This explosive growth is driven by the increasing adoption of digital twins across industries to optimize operations, reduce costs, and enhance decision-making through virtual replicas of physical assets. Digital twins integrate IoT, AI, and data analytics to simulate real-world…

Hemato Oncology Testing Market is Forecasted to Reach USD 23.64 Billion by 2033 …
The global hemato oncology testing market is valued at USD 4.33 billion in 2023 and is projected to expand at a compound annual growth rate (CAGR) of 18.5%, reaching USD 23.64 billion by 2033. This rapid growth is driven by the increasing prevalence of blood-related cancers, such as lymphoma and leukemia, and advancements in diagnostic technologies like next-generation sequencing (NGS) and polymerase chain reaction (PCR). Hemato oncology testing plays a…

Osseointegration Implants Market is Anticipated to Reach USD 6.85 Billion by 203 …
Osseointegration Implants Market is poised for robust growth, with its valuation projected to rise from USD 3.17 billion in 2025 to USD 6.85 billion by 2035, reflecting a compound annual growth rate (CAGR) of 8%. This expansion is driven by the increasing prevalence of orthopedic and dental disorders, such as osteoarthritis, rheumatoid arthritis, and edentulism, which necessitate advanced implant solutions. Osseointegration implants, which fuse directly with bone to provide stable…
More Releases for OTC
Lawsuit filed for Investors who lost money with shares of adidas AG (OTC: ADDYY, …
An investor, who purchased shares of adidas AG (OTC: ADDYY, OTC: ADDDF), filed a lawsuit over alleged violations of Federal Securities Laws by adidas AG in connection with certain allegedly false and misleading statements.
Investors who purchased shares of adidas AG (OTC: ADDYY, OTC: ADDDF) have certain options and for certain investors are short and strict deadlines running. Deadline: June 27, 2023. adidas AG (OTC: ADDYY, OTC: ADDDF) investors should contact…
Investigation for Investors in adidas AG (OTC: ADDYY, OTC: ADDDF) announced over …
An investigation on behalf of investors in shares of adidas AG (OTC: ADDYY, OTC: ADDDF) was announced over potential breaches of fiduciary duties by certain officers and directors at adidas AG.
Investors who purchased shares of adidas AG (OTC: ADDYY, OTC: ADDDF) have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.
The investigation by a law firm concerns whether certain adidas AG officers and…
AMERICAN HEMP VENTURES INC (OTC: AMHV) TO BECOME YOUNEEQAI TECHNICAL SERVICES In …
FOR IMMEDIATE RELEASE
Denver Colorado, March 31, 2023, American Hemp Ventures, Inc. (OTC: AMHV) announced today that its name has changed effective immediately to YouneeqAI Technical Services inc. (OTC: YQAI) reflecting the Company's new focus into cookie-less AI technology services.
The current management team has over 50 years of experience in technology services and innovation. Murray Galbraith, YQAI's CEO, is the Founder of YouneeqAI's software solution and has operated several private technology…
Investigation announced for Investors who lost money with shares of adidas AG (O …
An investigation was announced for investors of adidas AG (OTC: ADDYY, OTC: ADDDF) shares over potential securities laws violations by adidas AG.
Investors who purchased shares of adidas AG (OTC: ADDYY, OTC: ADDDF), have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.
The investigation by a law firm focuses on possible claims on behalf of purchasers of the securities of adidas AG (OTC: ADDYY,…
Fuel Cell Market Technological Trends and Business Opportunities 2021 To 2026; P …
MarketInsightsReports has published a report titled global Fuel Cell Market research report 2021 that is a detailed observation of several aspects, including the rate of growth, technological advances, and different methodologies implemented by the primary current market players. The report is based on a collective analysis of data, which is obtained through primary and secondary research. It provides a systematic approach to the current and prospective scenario of this market.
The…
Deadline on Nov. 9th upcoming in Lawsuit for Investors in Harborside Inc. (OTC: …
The Shareholders Foundation announced that a deadline is coming up on November 9, 2020 in the lawsuit filed for certain investors of Harborside Inc. (OTC: HSDEF, OTC: HBORF).
Investors who purchased shares of Harborside Inc. (OTC: HSDEF, OTC: HBORF) have certain options and there are strict and short deadlines running. Deadline: November 9, 2020. Harborside Inc. stockholders should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.
According to…